Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comment on: residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL.
Iannotti N, Masini G, Bernardini C, Soavi L, Cologni G, Malfatto E, Benatti S, Maggiolo F. Iannotti N, et al. Among authors: cologni g. J Antimicrob Chemother. 2012 Oct;67(10):2540-1; author reply 2541-2. doi: 10.1093/jac/dks233. Epub 2012 Jun 7. J Antimicrob Chemother. 2012. PMID: 22678729 No abstract available.
Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy.
Torti C, Prosperi M, Motta D, Digiambenedetto S, Maggiolo F, Paraninfo G, Ripamonti D, Cologni G, Fabbiani M, Caputo SL, Sighinolfi L, Ladisa N, El-Hamad I, Quiros-Roldan E, Frank I. Torti C, et al. Among authors: cologni g. Clin Microbiol Infect. 2012 May;18(5):449-58. doi: 10.1111/j.1469-0691.2011.03650.x. Epub 2011 Sep 15. Clin Microbiol Infect. 2012. PMID: 21919996 Free article. Clinical Trial.
Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received.
Motta D, Brianese N, Focà E, Nasta P, Maggiolo F, Fabbiani M, Cologni G, Di Giambenedetto S, Di Pietro M, Ladisa N, Sighinolfi L, Costarelli S, Castelnuovo F, Torti C. Motta D, et al. Among authors: cologni g. AIDS Res Ther. 2012 Jun 15;9(1):18. doi: 10.1186/1742-6405-9-18. AIDS Res Ther. 2012. PMID: 22703595 Free PMC article.
Early virological failure after tenofovir + didanosine + efavirenz combination in HIV-positive patients upon starting antiretroviral therapy.
Torti C, Quiros-Roldan E, Regazzi M, Antinori A, Patroni A, Villani P, Tirelli V, Cologni G, Zinzi D, Lo Caputo S, Perini P, Carosi G; KARINA-SISTHER Collaboration Group of the MASTER Cohort. Torti C, et al. Among authors: cologni g. Antivir Ther. 2005;10(4):505-13. Antivir Ther. 2005. PMID: 16038476 Clinical Trial.
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting.
Fabbiani M, Lombardi A, Colaneri M, Del Poggio P, Perini P, D'Ambrosio R, Degasperi E, Dibenedetto C, Giorgini A, Pasulo L, Maggiolo F, Castelli F, Brambilla P, Spinelli O, Re T, Lleo A, Rumi M, Uberti-Foppa C, Soria A, Aghemo A, Lampertico P, Baiguera C, Schiavini M, Fagiuoli S, Bruno R; NAVIGATORE-Lombardia Study Group. Fabbiani M, et al. J Viral Hepat. 2021 Mar;28(3):558-568. doi: 10.1111/jvh.13454. Epub 2021 Jan 2. J Viral Hepat. 2021. PMID: 33306247
Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.
Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group. Mocroft A, et al. PLoS Med. 2015 Mar 31;12(3):e1001809. doi: 10.1371/journal.pmed.1001809. eCollection 2015 Mar. PLoS Med. 2015. PMID: 25826420 Free PMC article.
28 results